Rare Disease Report

Serge Verstovsek, MD Discusses Myelofibrosis and Thrombocytosis

JUNE 05, 2017
Serge Verstovsek, MD

At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Rare Disease Report sat down with Serge Verstovsek, MD of the MD Anderson Cancer Center to discuss myelofibrosis and thrombocytosis, and the potential treatment options for both with the therapies ruxolitinib and azacytidine.

Among the questions asked were:
  • Describe the current treatment of thrombocytosis patients who are intolerant or resistant to hydroxyurea? (0:01)
  • Describe the phase 2 study involving ruxolitinib with azacytidine to treat myelofibrosis. (2:09)
  • Are any other studies currently being conducted with the combination of ruxolitinib and azacytidine? (3:41)
  • Can you provide an overview of the pathophysiology and treatment of thrombocytosis? (5:09)
  • Can you also speak to the pathophysiology and treatment of myelofibrosis? (6:23)

For more from ASCO, check out our Conference Coverage page.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.